Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

The
implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter
methylation were evaluated for prognostic outcome of glioma patients.
Methods:
Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation
by DNA sequencing and MS-PCR, respectively.
Results:
Mutations found in IDH1/2 genes totalled 63.4% (N=40) wherein IDH1 mutations
were significantly associated with oligidendrioglioma (p=0.005) and
astrocytoma (p=0.0002). IDH1mutants presented more, 60.5% in MGMT promoter
methylated cases (p=0.03). IDH1 mutant cases had better survival for GBM and oligodendrioglioma
(log rank p=0.01). Multivariate
analysis confirmed better survival in MGMT methylation carriers (HR: 0.59,
p=0.031). Combination of both biomarkers showed better prognosis on
temozolomide (p<0.05).

Conclusions: IDH1/2 mutations proved independent
prognostic factors in glioma and associated with MGMT methylation for better
survival.